Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Public ClinicalTrials.gov record NCT02342704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects
Study identification
- NCT ID
- NCT02342704
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Biogen
- Industry
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Interventions
- natalizumab Drug
- fingolimod Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2014
- Primary completion
- May 17, 2016
- Completion
- May 17, 2016
- Last update posted
- Jun 8, 2017
2014 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Colorado Springs | Colorado | 80907 | — |
| Research Site | Port Charlotte | Florida | 33952 | — |
| Research Site | Atlanta | Georgia | 30327 | — |
| Research Site | Des Moines | Iowa | 50314 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Knoxville | Tennessee | 37922 | — |
| Research Site | Round Rock | Texas | 78681 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Seattle | Washington | 98122 | — |
| Research Site | Tacoma | Washington | 98405 | — |
| Research Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02342704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2017 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02342704 live on ClinicalTrials.gov.